• Geoffrey C Nguyen, Karen Boland, Waqqas Afif, Brian Bressler, Jennifer L Jones, Adam V Weizman, Sharyle Fowler, Smita Halder, Vivian W Huang, Gilaad G Kaplan, Reena Khanna, Sanjay K Murthy, Joannie Ruel, Cynthia H Seow, Laura E Targownik, Tanya Chawla, Luis Guimaraes, Aida Fernandes, Sherif Saleh, and Gil Y Melmed.
• 1Mount Sinai Hospital IBD Centre, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; 2Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; 3Division of Gastroenterology, Department of Medicine, McGill University, Montreal, Québec, Ontario; 4St. Paul's Hospital, Department of Medicine, Division of Gastroenterology, University of British Columbia, Vancouver, British Columbia, Canada; 5Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; 6Division of Gastroenterology, Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; 7Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada; 8Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; 9Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; 10Division of Gastroenterology, Department of Medicine, University of Western Ontario, London, Ontario, Canada; 11The Ottawa Hospital IBD Centre, Department of Medicine, University of Ottawa, Ottawa, Canada; 12Division of Gastroenterology, Department of Medicine, Université de Sherbrooke, Sherbrooke, Quebec, Canada; 13Division of Gastroenterology, Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; 14Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada; 15Crohn's and Colitis Canada, Toronto, Ontario, Canada; and 16Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, California.
• Inflamm. Bowel Dis. 2017 Jun 1; 23 (6): 858-865.

Background And AimsThe prevalence and incidence of inflammatory bowel disease (IBD) in North America is among the highest in the world and imparts substantial direct and indirect medical costs. The Choosing Wisely Campaign was launched in wide variety of medical specialties and disciplines to reduce unnecessary or harmful tests or treatment interventions.MethodsThe Choosing Wisely list for IBD was developed by the Canadian IBD Network for Research and Growth in Quality Improvement (CINERGI) in collaboration with Crohn's and Colitis Canada (CCC) and the Canadian Association of Gastroenterology (CAG). Using a modified Delphi process, 5 recommendations were selected from an initial list of 30 statements at a face-to-face consensus meeting.ResultsThe 5 things physicians and patients should question: (1) Don't use steroids (e.g., prednisone) for maintenance therapy in IBD; (2) Don't use opioids long-term to manage abdominal pain in inflammatory bowel disease (IBD); (3) Don't unnecessarily prolong the course of intravenous corticosteroids in patients with acute severe ulcerative colitis (UC) in the absence of clinical response; (4) Don't initiate or escalate long-term medical therapies for the treatment of IBD based only on symptoms; and (5) Don't use abdominal computed tomography (CT) scan to assess IBD in the acute setting unless there is suspicion of a complication (obstruction, perforation, abscess) or a non-IBD etiology for abdominal symptoms.ConclusionsThe Choosing Wisely recommendations will foster patient-physician discussions to optimize IBD therapy, reduce adverse effects from testing and treatment, and reduce medical expenditure.

22 keywords...

hide…